TMC8 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8IU68 |
---|---|
Clone Names | 100517185 |
Gene ID | 147138 |
---|---|
Other Names | Transmembrane channel-like protein 8, Epidermodysplasia verruciformis protein 2, TMC8, EVER2, EVIN2 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | TMC8 |
---|---|
Synonyms | EVER2, EVIN2 |
Function | Probable ion channel. |
Cellular Location | Endoplasmic reticulum membrane; Multi-pass membrane protein |
Tissue Location | Expressed in placenta, prostate and testis. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Epidermodysplasia verruciformis (EV) is an autosomalrecessive dermatosis characterized by abnormal susceptibility tohuman papillomaviruses (HPVs) and a high rate of progression tosquamous cell carcinoma on sun-exposed skin. EV is caused bymutations in either of two adjacent genes located on chromosome17q25.3. Both of these genes encode integral membrane proteins thatlocalize to the endoplasmic reticulum and are predicted to formtransmembrane channels. This gene encodes a transmembranechannel-like protein with 8 predicted transmembrane domains and 3leucine zipper motifs.
References
McDermott, D.F., et al. Pediatr Dermatol 26(3):306-310(2009)Patel, A.S., et al. Int. J. Cancer 122(10):2377-2379(2008)Zavattaro, E., et al. J. Invest. Dermatol. 128(3):732-735(2008)Lazarczyk, M., et al. J. Exp. Med. 205(1):35-42(2008)Rady, P.L., et al. Br. J. Dermatol. 157(4):831-833(2007)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.